Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Targets Quick Launches For Zolgensma in Europe

Conditional Approval Finally Granted For SMA Gene Therapy

Executive Summary

The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.

You may also be interested in...



Roche Seeks Speedy EMA Review For SMA Drug Risdiplam

Applications to market Roche’s spinal muscular atrophy drug have already been submitted in eight countries including the US, where a decision is due in August.

Japan To Reimburse Zolgensma – But At Lower Price Than US

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Zolgensma ‘Lottery’ Attacked From All Sides

An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132353

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel